- Home
- WOLF vs BNTC Comparison
WOLF vs BNTC Comparison
Compare WOLF & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WOLF | BNTC |
|---|---|---|
| Founded | 1987 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 505.2M | 411.4M |
| IPO Year | 2025 | 2020 |
Fundamental Metrics
Financial Performance| Metric | WOLF | BNTC |
|---|---|---|
| Price | $25.57 | $12.14 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $14.33 | ★ $27.67 |
| AVG Volume (30 Days) | ★ 3.2M | 96.0K |
| Earning Date | 05-05-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 80.94 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,385,982,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.43 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 19.00 | N/A |
| 52 Week Low | $0.39 | $9.85 |
| 52 Week High | $36.60 | $17.15 |
Technical Indicators
Market Signals| Indicator | WOLF | BNTC |
|---|---|---|
| Relative Strength Index (RSI) | 55.13 | 49.61 |
| Support Level | $15.86 | $11.39 |
| Resistance Level | $34.29 | $13.06 |
| Average True Range (ATR) | 3.39 | 0.80 |
| MACD | 0.09 | -0.09 |
| Stochastic Oscillator | 35.00 | 33.94 |
Price Performance
Historical ComparisonAbout WOLF Wolfspeed Inc.
Wolfspeed Inc is involved in the manufacturing of wide bandgap semiconductors. It is focused on silicon carbide and gallium nitride materials and devices for power and radio-frequency (RF) applications. The company serves applications such as transportation, power supplies, inverters, and wireless systems. Geographically, it derives a majority of its revenue from Europe and the rest from the United States, China, Hong Kong, Asia Pacific, and other regions.
About BNTC Benitec Biopharma Inc.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.